Targeted therapy with open radioactive substances is highly effective and a central component of the field of nuclear medicine.

After a conversion phase of over 2 years, operations at the radionuclide therapy ward (ward 75) of the MHH was resumed in mid-2013. This means that a state-of-the-art unit for nuclear medicine treatments is now available. Important information on special features and rules of conduct on the ward can be found here.

Based on decades of experience and pioneering work in this field

benign and malignant thyroid diseases are successfully treated with safe and transparent indications.

The interdisciplinary, closely networked environment of the MHH is also used to develop innovative therapies such as

the peptide receptor radiotherapy (PRRT),

the PSMA ligand therapy,

the selective internal radiotherapy (SIRT) and its targeted use.